Ra Medical Systems Granted Patent for Support Catheter

Ra Medical Systems Inc. has strengthened its liquid core ablation catheter IP technology. 

The company has received a U.S. patent for a support catheter used with a small flexible liquid core catheter for laser ablation of arterial plaque blockages to restore blood flow. U.S. patent 11,241,519 B2, “Small Flexible Liquid Core Catheter for Laser Ablation in Body Lumens and Methods for Use,” describes a support catheter used in conjunction with the DABRA liquid core ablation catheter. Bench studies conducted by Ra Medical have demonstrated the utility of combining the DABRA ablation catheters with support catheters in navigating difficult peripheral vasculature.
 
“We now have patent protection for a support catheter that could expand the range of solutions for physicians who want to utilize our DABRA liquid core ablation catheters in challenging anatomies,” said Will McGuire, Ra Medical Systems CEO. “We believe this patent expands our strong intellectual property portfolio, which will be beneficial when we return the DABRA excimer laser system to full commercialization.”
 
Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of certain vascular diseases. DABRA has been cleared by the U.S. Food and Drug Administration for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.